Join to View Full Profile
200 Medical Plaza, Suite B265Los Angeles, CA 90095
Phone+1 310-825-9771
Fax+1 310-825-9771
Dr. Kishan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Radiation Oncology, 2013 - 2017
Scripps Mercy HospitalInternship, Transitional Year, 2012 - 2013
Harvard Medical SchoolClass of 2012
Certifications & Licensure
CA State Medical License 2014 - 2026
American Board of Radiology Radiation Oncology
Clinical Trials
- Stereotactic Body Radiation Therapy in Treating Patients with Localized Prostate Cancer That Have Undergone Surgery Start of enrollment: 2019 Jan 29
Publications & Presentations
PubMed
- Pelvic Regional Control With 25 Gy in 5 Fractions in Stereotactic Radiation Therapy for High-Risk Prostate Cancer: Pooled Prospective Outcomes From the SHARP Consortium.Vedang Murthy, Indranil Mallick, Priyamvada Maitre, Gargee Mulye, Moses Arunsingh
International Journal of Radiation Oncology, Biology, Physics. 2025-05-01 - A clustering-based approach to address correlated features in predicting genitourinary toxicity from MRI-guided prostate SBRT.Pouyan Rezapoor, Jonathan Pham, Beth Neilsen, Hengjie Liu, Minsong Cao
Medical Physics. 2025-04-23 - Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.Amar U Kishan, Kristen McGreevy, Luca Valle, Michael Steinberg, Beth Neilsen
Clinical Cancer Research. 2025-04-07
Journal Articles
- Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized,...James B Yu, Amar U Kishan, JAMA Network Open
Press Mentions
MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ Ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate CancerApril 7th, 2025- New Test Identifies Prostate Cancer Patients at Risk for Long-Term Radiation Therapy Side EffectsApril 7th, 2025
- Similar Efficacy Seen for Isodose, Dose-Escalated MHFRT, CFRT in Prostate CancerApril 2nd, 2025
- Join now to see all
Grant Support
- Reducing toxicity from prostate cancer radiotherapy through genetics and technologyUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
